No Special Heart Risk With JAK Inhibitors, Study Finds
(MedPage Today) -- Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Arthritis | Cardiology | Cardiovascular | France Health | Heart | Humira | Rheumatoid Arthritis | Rheumatology | Study